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A B S T R A C T
Objective: An adaptive design uses data collected as a clinical trial
progresses to inform modifications to the trial. Hence, adaptive
designs and health economics aim to facilitate efficient and accu-
rate decision making. Nevertheless, it is unclear whether the
methods are considered together in the design, analysis, and
reporting of trials. This review aims to establish how health eco-
nomic outcomes are used in the design, analysis, and reporting of
adaptive designs. Methods: Registered and published trials up to
August 2016 with an adaptive design and health economic
analysis were identified. The use of health economics in the design,
analysis, and reporting was assessed. Summary statistics are pre-
sented and recommendations formed based on the research team's
experiences and a practical interpretation of the results. Results:
Thirty-seven trials with an adaptive design and health economic anal-
ysis were identified. It was not clear whether the health economic
analysis accounted for the adaptive design in 17/37 trialswhere thiswas
thought necessary, nor whether health economic outcomes were used
at the interim analysis for 18/19 of trials with results. The reporting of
health economic results was suboptimal for the (17/19) trials with pub-
lished results. Conclusions: Appropriate consideration is rarely given
to the health economic analysis of adaptive designs. Opportunities to
use health economic outcomes in the design and analysis of adaptive
trials are being missed. Further work is needed to establish whether
adaptive designs and health economic analyses can be used together
to increase the efficiency of health technology assessments without
compromising accuracy.
Keywords: adaptive design, cost-effectivenes, clinical trials, value of
information
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Introduction
Decision makers such as the National Institute for Health and
Care Excellence (NICE) in the United Kingdom, the Canadian
Agency for Drugs and Technologies in Health, or the Pharma-
ceutical Benefits Advisory Committee in Australia require high-
quality evidence of both clinical effectiveness and cost-
effectiveness when making funding recommendations.1-3 Faced
with mounting ethical pressures and limited budgets, increasing
the efficiency of clinical trials research is a priority.4
Adaptive Designs
Adaptive designs use data collected as a trial progresses to inform
modifications to the trial, without compromising the validity or
integrity of the study.5 They have the potential to benefit patients
and healthcare providers ethically and financially6 and are
becoming a popular alternative to the traditional fixed sample size
trial in appropriate clinical circumstances.7,8 Table 1 summarizes
some adaptive design methods available. In addition, Chow and
Chang provide a comprehensive summary of adaptive designs,14
and Pallmann et al give real-world examples.17
The analysis following an adaptive design requires careful
consideration and it is important to account for the adaptive na-
ture of the study design. For example, when a group sequential
design (GSD) stops early the analysis may be biased.9 This has the
potential to influence a health economic analysis that relies on an
accurate estimate of the treatment effect and its associated con-
fidence interval. Further problems may arise when the health
economic outcomes, such as costs and quality of adjusted life
years (QALY), are correlated with the primary outcome.11
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Health Economics
The methods of economic evaluation facilitate the comparison of
the costs and benefits of alternative technologies to determine
which is the most cost-effective.19 Value of information analysis
(VOIA) methods assess whether it is worthwhile collecting further
information to inform a decision.19 Table 1 provides a summary of
key terms in health economic analyses; Drummond et al19 provide
a comprehensive summary.
Objectives
Adaptive designs could compromise accuracy by introducing bias
into health economic analyses. This has the potential to nega-
tively affect patients and healthcare providers. It is important to
have a clear understanding of how adaptive designs and health
economics are considered together in the design, analysis, and
reporting of clinical trials.
The primary aim of this review is to establish how health
economic outcomes are used in adaptive trials in the design,
such as secondary outcomes or informing sample size using
VOIA methods; analysis, such as whether adjustments were
used to account for the adaptive nature of the trial; and
reporting, by applying elements of established reporting
guidelines.24,25
Methods
Data Sources and Search Strategy
To identify a diverse and representative sample of adaptive de-
signs, six sources were used:
1. clinicaltrials.govda new review by this research team that in-
volves looking for trials with an adaptive design registered
from 2011 onward (accessed August 19, 2016).26
2. Peer-reviewed journals via MEDLINE, EMBASE, Cochrane Li-
brary, and Web of Scienceda new review aiming to identify
articles reporting the methods for health economic analysis of
adaptive designs. Any articles reporting a clinical trial with an
adaptive design were included in the current review.
3. Hatfield et al7dreviewed 158 registered clinical trials on
clinicaltrials.gov between 2000 and 2014 and the National
Institute for Health Research (NIHR) register and contacted
experts for known adaptive designs.
4. Stevely et al27dreviewed the reporting of 68 published clinical
trials using a GSD identified on MEDLINE for years 2001 to 2014.
5. Health Technology Assessment (HTA) journaldthe journal pub-
lishes research on the effectiveness, costs, and broader impact
of healthcare technologies used on the NHS, including the re-
sults of clinical trials funded by the NIHR Health Technology
Assessment Programme.
Table 1 – Glossary of key terms in the adaptive designs and health economics literature
Name Description
Group Sequential Design (GSD) Interim analyses are carried out after groups of patients have reached the outcome of interest.9,10 The trial
can stop early if there is sufficient evidence of safety, efficacy, or futility. The analysis following a GSD
requires careful consideration because of potential bias introduced by the stopping rules.11 Methods
exist to adjust for this bias in the treatment effect estimate and its confidence interval as well as
correlated secondary outcomes.11-13
Sample Size Re-estimation The sample size calculated before the trial commenced is updated using information collected up to the
interim analysis.14 This can be conducted blind to the treatment allocation or unblind. A blinded sample
size re-estimation does not require any statistical adjustment; nevertheless, when unblinded data are
used, the probability of making a type I error increases.15 Generally, these methods are recommended
only to increase the sample size.15
Adaptive Randomisation Modifications to the randomization procedure after the trial has commenced can be made based on the
allocation of previous participants in the trial.14 This can increase the probability of success of the trial
and allow new participants to receive the most promising treatment.14
Internal Pilot Internal pilots are usually undertaken to assess the feasibility of the trial as opposed to the feasibility of the
intervention. Decisions regarding whether a trial should progress are usually made in the context of
recruitment or retention rates within the trial. There could also be an opportunity to re-estimate the
sample size.16
Multi-Arm Multi-Stage Multi-Arm Multi-Stage (MAMS) trials allow multiple treatments to be compared with a single control arm.
The multiple stages (interim analyses) increase efficiency by allowing arms to be dropped for futility or
even for the whole trial to stop if efficacy can be demonstrated.17
Expected Value of Perfect
Information (EVPI)
The expected value of perfect information (EVPI) considers the scenario where further research would
eliminate all decision uncertainty,18 representing the most that can be gained from further research.19
The EVPI can take only positive values.20 It is potentially worthwhile conducting further research if the
associated costs are less than the EVPI.
Expected Value of Partially
Perfect Information (EVPPI)
It may not be feasible to collect further information about all the parameter inputs in a health economic
analysis. Instead, the expected value of partially perfect information (EVPPI) can be calculated using the
same idea as the EVPI calculation.21
Expected Value of Sample
Information (EVSI)
The methods of EVPI and EVPPI estimate the value of eliminating all or an element of uncertainty in a
decision problem. It is not, however, always possible to do this. It may be more feasible to consider the
value of reducing some of the uncertainty,22 for example, by conducting another clinical trial or
continuing with an adaptive design when presented with interim data. The expected value of sample
information (EVSI) can be used to determine the value of a specific research design that will be used to
inform a decision.23
Economic Evaluation “Comparative analysis of alternative courses of action in terms of both their costs and consequences.”19
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6. Known adaptive designsdidentified by contacting experts in
statistics and health economicsdknown to the research team
and via emails sent to the online forums AllStat (Sep. 28, 2016)
and HealthEconAll (Sep. 29, 2016).
To identify articles on clinicaltrials.gov and the HTA journal
the search strategy implemented by Hatfield et al7 (see Appendix 1
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
018.11.008) was used. The strategy aimed to identify trials with an
adaptive design using common words such as “adaptive,”
“sequential,” and “interim.” Development and validation of the
strategy is reported in Hatfield et al.7
Inclusion Criteria
Five reviewers [F.A., R.B., L.F., S.A.J., K.P.] identified articles that
met criteria adapted from Hatfield et al7:
1. Trial documentation available in English
2. Phase III clinical trial
3. Trial investigating an intervention(s) on humans with a
comparator
4. Registered or published before Aug. 1, 2016
5. Multiple treatment arms
6. An adaptive design clinical trialddefined to be a trial with any
preplanned early examination of the data, including any
monitoring of the data by a data monitoring and ethics com-
mittee (DMEC) where it is clear that there had been or there is a
planned formal analysis of the data
7. A planned health economic analysis
The chief investigator for clinical trials with a preplanned
adaptive design but with no clear health economic analysis was
contacted via email to ask whether any health economic analyses
were carried out.
Data Extraction
For trials that met the inclusion criteria, information was
extracted relating to their characteristics, design, analysis, and
reporting. A data extraction sheet was developed using items from
five key checklists or quality assessment processes in the areas of
clinical trials, health technology assessment, and cost-
effectiveness, including the CONSORT statement and the
CHEERS checklist.24,25,28-30
We identified trial documentation using the information from
trial registries, protocols, and journal publications (identified via
MEDLINE and Google Scholar). When a large number of results
were returned by a database, they were sorted by relevance and
date to identify the most relevant publications. To assess the
reporting of the trial results we used the main trial paper or HTA
monograph.
Inclusion criteria were applied and data were extracted inde-
pendently by two reviewers. Any discrepancies were resolved by a
group discussion. All data were checked and cleaned by [L.F.].
Some of the information extracted, such as the level of detail re-
ported about health economics in the protocol and reporting
questions, required a subjective decision, and [L.F.] therefore
reviewed data extracted by the team andmade a final decision for
consistency. Any subsequent changes were documented.
Outline of Analysis
A descriptive analysis was undertaken to provide an overview of
how health economics was used in the sample of adaptive de-
signs. Continuous variables were summarized using their mean
and standard deviation (SD). Categorical variables were summa-
rized using counts and percentages.
Results
A total of 553 articles were identified (see Fig. 1). Of these, 278 were
identified on clinicaltrials.gov and 159were registered before 2011.
[L.F.] applied the inclusion criteria to a subsample of 79/159
clinicaltrials.gov articles from 2010 or earlier. In this subsample,
only one trial was found to meet the inclusion criteria. It was
decided to omit the 159 clinicaltrials.gov trials registered before
2011 from the review. This decision is justified by the work of
Hatfield et al that found that adaptive designs were increasingly
used between 2012 and 2013.7 Given the small number of articles
identified in the subsample, it is unlikely that many trials have
been missed.
Thirty-seven trials met the inclusion criteria and were subject
to full data extraction.
Trial Characteristics
All trial characteristics are summarized in Table 2. The types of
adaptive designs identified are summarized in Table 3. One trial
did not provide sufficient information to assess themethods used.
It was common for multiple adaptations to be implemented in a
single trial. Table 3 includes all the adaptations.
The rationale for choosing an adaptive design was clear in 38%
(14/37) of trials. The most common rationale was to check the
uncertain assumptions made at the design stage of the trial. For
example, the EVIDENCE study31 identified that there was a lack of
information to inform their sample size. They preplanned an
interim analysis to re-estimate the required number of patients to
achieve sufficient statistical power.
Health Economics in the Design
A trial protocol was identified in 73% (27/37) of the trials. The
prespecification of health economic analyses was limited with
41% (11/27) of trials not providing any detail and 59% (16/27)
providing only limited detail in the trial protocol, such as a para-
graph outlining that a Markov model would be used for the health
economic analysis but little further elaboration. A total of 15% (4/
27) of trials included a full analysis plan for their proposed sta-
tistical analyses in their protocol, and 85% (23/27) provided limited
detail. Fifty-two percent (14/27) of the trials reported limited detail
relating to both their health economic and statistical analyses.
Some trials may have reported a full statistical analysis or health
economic analysis plan in a separate document not appended to
the protocol, which we have not captured.
The role of health economic outcomes in the design of the
adaptive trials was limited (see Table 4). “GDHT,”32-34 “PRESSURE-
2,”35 and “OPTIMA”36-38 were considered to have used health
economics in their design. The OPTIMA trial listed a health eco-
nomic outcome as a primary outcome; nevertheless, this was not
considered in any sample size calculation. The Persephone study
listed costs and quality of life outcomes in relation to their study
design, but it was not clear what role these outcomes took.39
OPTIMA considered using VOIA to inform their design and
PRESSURE II planned to include an EVSI analysis at an interim.
Health Economics in the Analysis Conducted
Information about the analysis of the adaptive designs was
extracted from trials with results available (51% [19/37]). The
remaining 18 trials did not have any results at the time of data
extraction and so were not included.
Of the 19 trials, we identified those thought to require adjust-
ment to their analysis to allow for the adaptive nature of the
design, specifically trials using a GSD. The reporting of the
methods was not always explicitly clear and a judgment was
made about the need for adjustment. Where a trial simply stated
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that there was an interim analysis (4 trials), it was assumed that
this was a GSD, as this is the most common type of adaptation
used in practice as identified by Hatfield et al, where 78% of phase
III trials used a GSD.7,40 Two of the 19 trials were not thought to
have used sequential methods or required adjustment; one used
adaptive randomization and the second a sample size re-
estimation.
In the remaining 17/19 trials, for which an adjustment of the
point estimate for the primary and any correlated secondary
outcomes was thought appropriate, there was no clear indication
that the primary outcome was adjusted. In addition, none of the
17 trials indicated whether they used adjusted primary or sec-
ondary outcomes in their health economic analysis.
Health Economic Analysis Using Interim Data
Tessitore et al reported the interim analysis of a randomized trial
on the elective repair of subclinical stenosis (ISRTC69115386).41
The authors calculated the cost-effectiveness of the intervention
using the interim data. They concluded that, given a large clinical
benefit of the intervention and little difference in cost, it was
unethical to continue the trial. There was no indication as to
whether the treatment effect estimate was adjusted for the
interim analysis.
Health Economics in the Reporting
Of the 19 trials with results available, 1 trial provided results only
on clinicaltrials.gov and a second had information only in a short
conference abstract; therefore, it was not possible to assess their
Table 2 – Summary of the trial characteristicsmeeting the
inclusion criteria.
Characteristic Category n %
State Ongoing 8 22
Recruiting 7 19
Completed 20 54
Not clear 2 5
Country of chief
investigator
Canada and USA 9 24
China 1 3
Europe (not including UK) 9 24
UK 17 46
Funder Private 6 16
Public 25 68
Private and public 2 5
Not clear 4 11
Experimental treatment Medicinal 17 46
Device 3 8
Educational 2 5
Psychological 0 0
Complex intervention 0 0
Other 15 41
Comparator Active 35 95
Placebo 2 5
Therapeutic area Oncology 11 30
Cardiology 5 14
Vascular and hematology 4 11
Spinal 2 5
Other 15 41
Table 3 – Summary of how health economic outcomes
were considered in the design of the adaptive design
clinical trials in the review.
Characteristic Category n %
Were health economic outcomes
considered in the design?
Yes 3 8
No 32 86
Not clear 2 5
Were any health economic outcomes
a primary outcome?
Yes 1 3
No 34 92
Not clear 2 5
Were health economic outcomes considered
in the sample size calculation?
Yes 0 0
No 34 92
Not clear 3 8
Was value of information analysis
considered in the design?
Yes 2 5
No 32 86
Not clear 3 8
Two trials were conference abstracts and the third did not have a
protocol available.
Fig. 1 – Flow of articles through the review.
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reporting. Table 5 summarizes how well the trials reported their
results.
There was little consideration for how the adaptive design
might impact the clinical and a health economic analyses. One
trial discussed how stopping at an interim analysis resulted in less
data and therefore greater uncertainty in the health economic
analysis. The authors also acknowledged that this would likely
affect the generalizability of their results. It was clear for only one
trial that prior interim results were available and were discussed
at a conference and disseminated to trial participants.
Exemplars
The following trials highlight the use of adaptive designs and
health economics as part of the clinical trial process. None of the
exemplars seem to use health economics and adaptive designs to
their full potential or consider the impact that using data from an
adaptive design might have on their analysis. Nevertheless, given
the limited research and awareness in this area, these trials
illustrate the potential use of these methods.
Exemplar 1: OPTIMA Trial
The optimal personalized treatment of breast cancer using
multiparameter analysis (OPTIMA) trial illustrated how VOIA
methods could be used to inform the design and conduct of an
adaptive design.36-38The OPTIMA trial was designed to explore the
personalized treatment of breast cancer by using laboratory tests
to determine who should receive chemotherapy. This trial was an
adaptive design with two interim analyses assessing futility and
noninferiority.
The OPTIMA trial was preceded by a cost-utility analysis38
using health economic modeling to determine the cost-
effectiveness of genomic test-directed chemotherapy and
chemotherapy for all patients. VOIA was used to inform the value
of conducting further research and highlight areas that required
further work. This showed substantial uncertainty in the cost-
effectiveness, and hence the OPTIMA prelim study was planned.
The OPTIMA prelim trial (ISRCTN42400492) was used to assess
the feasibility of a larger trial. One of the main objectives was to
evaluate the performance and health economics of different lab-
oratory tests to determine what would be evaluated in the main
trial. The analysis highlighted considerable uncertainty in the
cost-effectiveness of all the tests.42 A VOIA suggested that there
was high value in conducting further research. The EVSI calcula-
tion for a large trial with 2500 patients per arm, comparing
chemotherapy for all patients with chemotherapy directed by one
of the tests under consideration, was £8,397,961 for the 10-year
incident population, suggesting value in carrying out this research
design. Nevertheless, this calculation does not appear to have
informed the sample size calculation for the OPTIMA trial.37
The OPTIMA program of research highlighted the opportu-
nities to use VOIA to design efficient trials by including a stop-go
decision before the full trial. A possible extension of these
methods could have been to use the stop-go criteria at the interim
Table 4 – Summary of the adaptations used in a trial.
Type of adaptation n %
Adaptive randomization 1 2
Drop the loser 2 3
Internal pilot 12 20
Sample size re-estimation 7 12
Efficacy 3 5
Efficacy and futility 4 7
Efficacy and safety 9 15
Futility 5 8
Futility and noninferiority 1 2
Futility and safety 1 2
Futility and safety and efficacy 5 8
Interim* 4 7
NA 1 2
All adaptations discussed in a particular trial are included. There-
fore, percentages are expressed in terms of the total number of
adaptations.
* Interim denotes a trial where an interim examination of the data
wasmentioned but it was not possible to ascertain themotivation
or methods used.
Table 5 – Summary of the level of reporting in the
adaptive design (AD) clinical trials in the review.
Characteristic Category n %
Was the trial identified as an
adaptive design in the title?
Yes 1 3
No 16 43
NA 20 54
Was the economic evaluation or
more specific identified in the title?
Yes 5 14
No 12 32
NA 20 54
Was the economic evaluation or
more
specific identified in the abstract?
Yes 8 22
No 9 24
NA 20 54
Were health economic outcomes
discussed on the main trial paper?
Yes 9 24
No 8 22
NA 20 54
Discussion of how the adaptive
design
might have impacted on the health
economic analysis
Yes 1 3
No 14 38
Trial stopped
before first
interim
2 5
NA 20 54
Was the potential for bias in the
results discussed?
Yes 0 0
No 15 41
Trial stopped
before first
interim
2 5
NA 20 54
Was the generalizability of the
findings from the adaptive design
discussed?
Yes 1 3
No 14 38
Trial stopped
before first
interim
2 5
NA 20 54
Were lessons learnt from using the
adaptive design discussed?
Yes 0 0
No 15 41
Trial stopped
before first
interim
2 5
NA 20 54
Were prior interim results provided
or discussed?
Yes 1 3
No 11 30
Trial stopped
before first
interim
2 5
Trial stopped at
first interim
3 8
NA 20 54
Questions have been adapted9,27,29-31 (n ¼ 37).
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analysis to inform whether to stop or continue with the adaptive
trial with appropriate adjustments.
Exemplar 2: GDHT trial
The GDHT study for patients with proximal femoral fracture
included an interim analysis on efficacy and safety after 100 (from
a planned 460) patients had been recruited. At this point it was
decided to continue with the trial; nevertheless, after 50 further
patients were enrolled over the following 12 months, the decision
was made to stop the study.32-34
Before the trial, the authors developed a probabilistic decision
analytic cost-effectiveness model. The pretrial modeling high-
lighted that postoperative complications heavily influence the
cost-effectiveness of GDHT, and so the trial was designed to
assess the risk of postoperative complications and their influence
on quality of life. The pretrial model was then used for a VOIA
using interim data. Although this VOIA was not preplanned, the
authors highlight the potential for VOIA to be used in this way.
This study is a useful case study for using VOIA during an adaptive
design to inform whether it is cost-effective to continue with a
trial-based health economic grounds.
Exemplar 3: PRESSURE 2 trial
The PRESSURE 2 trial aimed to determine the clinical effectiveness
and cost-effectiveness of high specification foam and alternating
pressure mattresses for the prevention of pressure ulcers.35
Because there were no results available at the time of data
extraction, only the use of health economics in the design of the
trial was considered. The PRESSURE 2 considered the cost-
effectiveness of the research using interim data as part of an
EVSI calculation. This analysis will use the interim data to deter-
mine whether it is cost-effective to continue with the trial from an
NHS decision makers' perspective. This illustrates how health
economic outcomes can be used as part of the interim analysis of
an adaptive design.
Discussion
In our review of 37 clinical trials with an adaptive design and
health economic analysis, only 3 trials used health economic
outcomes in the design, and none of the trials seemed to appro-
priately adjust the health economic outcomes to account for
biases introduced by the adaptive study design. One study used
health economic outcomes at the interim analysis in the 19 trials
with results. The reporting of health economic results was sub-
optimal for all trials.
Trial Characteristics
We found that themajority of trials were UK based and 68% (25/37)
of trials were publicly funded. In the previous review by Hatfield
et al, adaptive designs were found to be predominantly conducted
in the United States and Canada.7 In addition, Hatfield et al7 and
Stevely et al27 found that industry-funded trials were more com-
mon with 101/143 and 35/68 trials, respectively. This contrast
could reflect the important role of health economic analyses in
healthcare decision-making in the public UK setting.1
Design
Although VOIA was considered by two trials, none discussed
using VOIA to inform their adaptive design, such as the optimal
number of interim analyses. This highlights a missed opportunity
to potentially increase the efficiency of adaptive designs by using
health economic outcomes to identify the most cost-effective
design.
Analysis
We found that many authors were not adjusting their clinical or
health economic analyses to allow for the adaptive nature of the
trial. A similar finding was reported by Stevely et al,27 who found
that the bias correction for early stopping (for clinical effective-
ness outcomes) was reported only in 7% (3/46) of GSDs.
The interim analysis of an adaptive design presents an op-
portunity to maximize the available interim data by considering:
 Clinical effectiveness
 Cost-effectiveness of the intervention using a cost-
effectiveness analysis
 Cost-effectiveness of the research using a VOIA
Currently these opportunities are rarely being used.
Reporting
We identified that the reporting of adaptive designs with health
economic analyses was poor. Reporting guidelines for the results
of clinical trials impacts the design, conduct, and analysis by
leaving no place for bad practice or poor choice of methods to be
hidden.24 Poor reporting makes it difficult for researchers using
the results of the trial to identify whether an adaptive design was
used and that analyses may need to be adjusted. Given the
importance of cost-effectiveness to decisionmakers, it is vital that
information can be easily identified so that the whole body of
evidence can be considered. There is also no opportunity for re-
searchers to learn from past research to improve their own
adaptive designs with a health economic analysis. These findings
reiterate Stevely et al,27 who found that reporting of clinical out-
comes was limited and highlight that this issue also extends to
health economic outcomes.
Reflection on the Current Methodological Literature
The use of health economics to inform the design and interim
monitoring of adaptive designs has received some attention in
the methodological literature. A number of authors use Bayesian
decision theory with dynamic programming methods to incor-
porate costs and utility into sequential decision problems. Berry
and Ho43 determined stopping boundaries for a one-sided
sequential clinical trial, where consequences of possible de-
cisions were considered explicitly on a monetary scale. Their
approach allows the trial to stop early if there is sufficient evi-
dence to suggest that it is futile to continue. This approach has
been extended by authors such as Lewis et al,44,45 Cressie and
Biele,46 and Mu¨ller et al.47
More recently, Willan and Kowiger48 considered the use of
EVSImethods to determine the optimal sample size formultistage
clinical trials. This work was extended by Chen andWillan49 to an
industry perspective. Pertile et al50 used a Bayesian sequential
economic evaluation model to approximate an optimal stopping
rule based on cost-effectiveness. The rule considers the cost of
carrying out further research against the value gained from hav-
ing a more accurate estimate of cost-effectiveness. Chick et al51
extended this to consider trials with a delay in observing the
response.
This review has highlighted how these methods are yet to
translate into practice. Possible explanations are that some of the
proposed methods have a high computational burden,52-54
requiring backward induction methods, and can be considered
only in a limited number of scenarios. Newer methods have not
yet had the chance to be applied in practice and reported.48,50,51
At the time of writing, we are not aware of any literature that
discusses the impact of adaptive designs on the health economic
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analysis, specifically the potential for bias to be introduced by the
adaptive design.
Limitations of This Work
The sample of adaptive designs reviewed were identified from a
range of sources; nevertheless, this will not include every adaptive
design. We chose to exclude trials identified using clinicaltrials.
gov before 2011; nevertheless, given the limited use of adaptive
designs before this time we do not believe that this exclusion will
affect the representativeness of our sample. The level of detail
provided on clinicaltrials.gov can vary, which meant that many
trials were excluded because there was insufficient information to
determine whether it was an adaptive design. This issue was also
faced by Hatfield et al.7 The trials in which a health economic
analysis was planned after the adaptive design was proposed
were not captured. There are likely to be consequences for these
types of analyses if they use data from adaptive trials too and this
should be considered when planning such analyses.
A number of the main trial reports did not give details about
health economic analyses conducted, and so it was difficult to
ascertain the methods used and whether any adjustments were
made for the adaptive nature of the trial.
Recommendations
We recommend that proposed health economic analyses should
be outlined in a detailed Health Economic and Decision Modelling
Analysis Plan (HEDMAP) before the start of an adaptive design.
Although this is recommended by the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)55 this was
not commonplace. Prespecification of all analyses is important in
adaptive designs to protect the validity and integrity of the re-
sults,5 especially for trials using health economic analyses to
inform interim decision making. Ideally, guidance developed for
the use of health economic analysis plans56 should consider
specific guidance for adaptive designs.
To improve the reporting of the health economic analysis of
adaptive designs the CHEERS checklist should be extended for
adaptive designs. The ongoing ACE project aims to develop
CONSORT guidelines tailored to the specific requirements of an
adaptive design,57 an important issue identified in reviews by
Stevely et al,27 Mistry et al,40 and Bothwell et al.8 Extending this
statement will address some of the reporting issues identified in
this review; nevertheless, the CONSORT guidelines do not include
the reporting of health economics. Appropriate points from these
guidelines should be applied to clinical trial registries and in the
trial protocol.
Conclusions
Appropriate consideration is rarely given to the health economic
analysis of adaptive designs. This could mean that trials are
stopping early based on efficacy outcomes but with insufficient
evidence to demonstrate the cost-effectiveness of the health
technology; continuing unnecessarily when there is already suf-
ficient evidence for decision making with respect to cost-
effectiveness; and drawing incorrect conclusions in the health
economic analysis as the bias introduced by the study design has
not been accounted for in the analysis.
Exploration of the methodological challenges and identifica-
tion of the practical and ethical issues are required to establish
whether adaptive designs and health economic analyses can be
used together to increase the efficiency of health technology as-
sessments without compromising accuracy.
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